Drug prices in Latin American countries: the case of rheumatoid arthritis Biosimilars

被引:5
|
作者
Mosegui, Gabriela Bittencourt Gonzalez [1 ]
Antonanzas, Fernando [2 ]
de Mello Vianna, Cid Manso [3 ]
Rojas, Paula [2 ]
机构
[1] Fluminense Fed Univ, Dept Hlth & Soc, Rua Marques Parana 303,3 Floor,Annex Bldg, BR-24033900 Niteroi, RJ, Brazil
[2] Univ La Rioja, Econ Fac, Dept Econ & Co, Calle Ciguena 60, Logrono 26006, La Rioja, Spain
[3] Rio De Janeiro Estadual Univ, Hlth Med Inst, Dept Hlth Policy Planning & Management, Rua Sao Francisco Xavier 524 Maracana,Bloco D, BR-20550013 Rio De Janeiro, RJ, Brazil
关键词
Biological products; Antirheumatic agents; Access to essential medicines and health technologies; Products registration; Drug Price;
D O I
10.1186/s42358-021-00172-w
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The objective of this paper is to analyze the prices of biological drugs in the treatment of Rheumatoid Arthritis (RA) in three Latin American countries (Brazil, Colombia and Mexico), as well as in Spain and the United States of America (US), from the point of market entry of biosimilars. Methods We analyzed products authorized for commercialization in the last 20 years, in Brazil, Colombia, and Mexico, comparing them to the United States of America (USA) and Spain. For this analysis, we sought the prices and registries of drugs marketed between 1999 and October 1, 2019, in the regulatory agencies' databases. The pricing between countries was based on purchasing power parity (PPP). Results The US authorized the commercialization of 13 distinct biologicals and four biosimilars in the period. Spain and Brazil marketed 14 biopharmaceuticals for RA, ten original, four biosimilars. Colombia and Mexico have authorized three biosimilars in addition to the ten biological ones. For biological drug prices, the US is the most expensive country. Spain's price behavior seems intermediate when compared to the three LA countries. Brazil has the highest LA prices, followed by Mexico and Colombia, which has the lowest prices. Spain has the lowest values in PPP, compared to LA countries, while the US has the highest prices. Conclusion The economic effort that LA countries make to access these medicines is much higher than the US and Spain. The use of the PPP ensured a better understanding of the actual access to these inputs in the countries analyzed.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Drug prices in Latin American countries: the case of rheumatoid arthritis Biosimilars
    Gabriela Bittencourt Gonzalez Mosegui
    Fernando Antõnanzas
    Cid Manso de Mello Vianna
    Paula Rojas
    Advances in Rheumatology, 61
  • [2] Educational website incorporating rheumatoid arthritis patient needs for Latin American and Caribbean countries
    Massone, Francisca
    Eugenia Martinez, Maria
    Pascual-Ramos, Virginia
    Quintana, Rosana
    Stange, Lilith
    Caballero-Uribe, Carlo V.
    Ferreyra-Garrot, Leandro
    Kourilovitch, Maria
    Duarte, Margarita
    Baumert, Carlos
    Vergara, Cristian
    Gareca, Nestor
    Rodriguez, Cecilia
    Khoury, Vianna
    Medina, Mariela
    Cardiel, Mario H.
    Massardo, Loreto
    CLINICAL RHEUMATOLOGY, 2017, 36 (12) : 2789 - 2797
  • [3] Educational website incorporating rheumatoid arthritis patient needs for Latin American and Caribbean countries
    Francisca Massone
    María Eugenia Martínez
    Virginia Pascual-Ramos
    Rosana Quintana
    Lilith Stange
    Carlo V. Caballero-Uribe
    Leandro Ferreyra-Garrot
    María Kourilovitch
    Margarita Duarte
    Carlos Baumert
    Cristián Vergara
    Néstor Gareca
    Cecilia Rodríguez
    Vianna Khoury
    Mariela Medina
    Mario H. Cardiel
    Loreto Massardo
    Clinical Rheumatology, 2017, 36 : 2789 - 2797
  • [4] A review of biosimilars for rheumatoid arthritis
    Conran, Carly A.
    Moreland, Larry W.
    CURRENT OPINION IN PHARMACOLOGY, 2022, 64
  • [5] EMPLOYMENT AND QUALITY OF LIFE AMONG PATIENTS WITH RHEUMATOID ARTHRITIS IN FOUR LATIN-AMERICAN COUNTRIES
    Xavier, R. M.
    Morales-Torres, J.
    Ramos-Remus, D. C. R.
    Chalem, P.
    Molina, J. F.
    Duhau, J.
    Perez-Gilbe, A.
    Carnide, E. M. G.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 996 - 996
  • [6] EMPLOYMENT AND QUALITY OF LIFE AMONG PATIENTS WITH RHEUMATOID ARTHRITIS IN FOUR LATIN-AMERICAN COUNTRIES
    Xavier, Ricardo
    Morales-Torres, Jorge
    Ramos-Remus, Diego
    Chalem, Phillipe
    Molina, Jose
    Duhau, Javier
    Carnide, Eugenia
    Perez-Gilbe, Annette
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2016, 22 (03) : 127 - 127
  • [7] PAYER AND PHYSICIANS EVIDENCE AND DISCOUNT EXPECTATIONS FOR BIOSIMILARS IN SIX LATIN AMERICAN COUNTRIES
    Sandorff, E.
    Bruni, Severi D.
    Halbert, R.
    VALUE IN HEALTH, 2013, 16 (07) : A667 - A667
  • [8] Payer and physician evidence and discount requirements for biosimilars in three Latin American countries
    Sandorff, Erik
    Pinheiro, Andre Vidal
    Bruni, Daniele Severi
    Halbert, Ronald J.
    Azevedo, Valderilio Feijo
    GABI JOURNAL-GENERICS AND BIOSIMILARS INITIATIVE JOURNAL, 2015, 4 (01): : 11 - 16
  • [9] Latin American Genes: The Great Forgotten in Rheumatoid Arthritis
    Diaz-Pena, Roberto
    Quinones, Luis A.
    Castro-Santos, Patricia
    Duran, Josefina
    Lucia, Alejandro
    JOURNAL OF PERSONALIZED MEDICINE, 2020, 10 (04): : 1 - 17
  • [10] Current therapies in rheumatoid arthritis: A Latin American perspective
    Burgos-Vargas, Ruben
    Jose Catoggio, Luis
    Galarza-Maldonado, Claudio
    Ostojich, Kasmir
    Cardiel, Mario H.
    REUMATOLOGIA CLINICA, 2013, 9 (02): : 106 - 112